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Background: Rehabilitational programs at moderate altitude (1500- 2500 m) showed 
improvement of lung function and reduction in airways inflammation in asthmatic 
adults. Allergen avoidance was postulated as the major cause of these 
improvements.
Methods: Spirometries of 344 and fractional exhaled nitric oxide measurements 
(FeNO) of 124 asthmatic children and adolescents, staying in a rehabilitation hospital 
in Davos (1590 m) with at least 14 days between admission and discharge, were ana-
lyzed in association with atopic sensitization (skin- prick testing and/or specific IgE), 
level of asthma control, and inhalative corticosteroid (ICS) dose.
: Pulmonary conditions improved significantly on average during the sojourn. 
Uncontrolled asthmatics benefited most with an absolute increase in predicted FEV1, 
MEF25, and MEF75 of 7.7%, 9.9%, and 12.7%, respectively (P < .001). FeNO decreased 
by 36.9 ppb for uncontrolled, by 26.9 ppb for partly controlled, and by 11.8 ppb for 
controlled asthmatics. In uncontrolled subjects, pulmonary improvement was compa-
rable between patients with and without house dust mites (HDM) sensitization. 
Pulmonary improvements of pollen- sensitized patients were not dependent on the 
season of the sojourn. For the group with constant ICS level, the absolute increase in 
FEV1 was 4.9% (P < .001) with a FeNO decreased by 32.7 ppb (P < .001). When the 
ICS dose was elevated by one GINA level, the absolute increase in FEV1 was slightly 
higher (6.6%, P < .001), with a FeNO decrease of 31.4 ppb (P < .001).
Conclusion: Inpatient rehabilitation at moderate altitude improved pulmonary condi-
tions in asthmatic children and adolescents independent of sensitization status to 
HDM or pollen. A positive effect was also observed in patients without change in 
medication.
adolescents, asthma, children, Davos, Forced expiratory volume in 1 second, Fractional exhaled 
nitric oxide, inflammation, pulmonary function, rehabilitation
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Asthma in children and adolescents is a serious health impairment.1 
Prevalence rates of asthma vary, according to countries2: due to dif-
ferences in the definition of asthma,3 due to inhomogeneous study 
populations, and most likely due to environmental factors. Asthma is 
frequently associated with comorbidities like obesity and atopic dis-
eases such as atopic dermatitis.4 In children and adolescents, asthma is 
often accompanied by psychosocial problems, poorer academic- , and 
professional performance and negatively affects the quality of life of 
the family.5,6 The GINA guidelines are effective for most asthmatic pa-
tients.7 However, in patients in which the controlled level of asthma is 
hard to maintain,8-10 a broader approach is needed to address all inter-
fering comorbidities and concomitants of the patient. A feasible option 
is a multidisciplinatory- rehabilitational, inpatient setting.11 A previous 
study of an inpatient rehabilitation program showed improvements of 
mid- expiratory flow und airway inflammation of forty- eight asthmatic 
children sensitized to HDM at moderate altitude.12
In our study, we investigated the overall effect of an inpatient re-
habilitation program at the Hochgebirgsklinik Davos on pulmonary 
function and airway inflammation of asthmatic children and adoles-
cents. Allergic sensitization, level of asthma control, and level of ICS 
dosage were included in our association study.
The hospital has its expertise in a multidisciplinatory- rehabilitational 
treatment for chronic respiratory, skin, and allergic diseases and is lo-
cated 1590 m above sea level in the Swiss Alps. In Davos, environmental 
investigations showed a very low indoor HDM concentration13 combined 
with low outdoor pollen concentration,14 especially when compared to 
lowland areas. Patients included in this investigation originated all from 
German lowlands. German pension insurance regulations entitle children 
and adolescents with asthma and/or atopic eczema for a minimum stay 
of 21 days in a specialized rehabilitation clinic every 5 years. The rehabil-
itation program provided by the hospital is based on the GINA guidelines 
and the Swiss recommendation for treatment of obstructive pulmonary 
diseases in childhood15,16 and consists of multiple parts. The first part is 
the diagnosis confirmation within the first 2- 3 days including differential 
blood, standard specific IgE panel, standard prick test, spirometry, ex-
haled NO test, and/or a methacholine challenge. If required, the patient 
will receive an adjustment of medication according to the clinical course 
in the last twelve months and during follow- up during the rehabilitation 
program. The second part of the rehabilitation program consists of pa-
tients and/or parents educational lessons about disease theory, manage-
ment and prevention, breathing techniques, inhaler use, nutrition, etc. 
Thirdly, physical in- and outdoor activities are a daily routine for all pa-
tients to improve their overall fitness level. For selected patients, psycho-
social therapy (psychotherapy, ergotherapy) is performed if necessary.
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Retrospective data analysis of 134 female and 210 male rehabilita-
tion patients (4- 19 years of age; mean 10.5 years) staying at the 
Hochgebirgsklinik Davos during January 2012 until October 2013 was 
performed. Inclusion criteria were a physician diagnosis of asthma or 
current asthma symptoms and two spirometries, with at least 14 days 
between admission and discharge.
|
Prior to admission, patients or their parents answered a questionnaire 
about their clinical history. Patients were classified into three asthma 
control level groups (controlled, partly controlled, and uncontrolled) 
according to GINA 2016 guidelines.
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Pulmonary function was assessed by spirometry (Master Screen 
Body, Jäger) for controlled (n = 61), partly controlled (n = 155), and 
uncontrolled asthma patients (n = 128). Outcome parameters were 
the forced expiratory volume in 1 second (FEV1), maximum expiratory 
flow at 25% (MEF25) and 75% (MEF75) compared between admission 
and discharge. The differences between admission and discharge are 
reported as absolute changes from the percent predicted value.
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Measurement of fractional exhaled nitric oxide (FeNO) was assessed 
as airway inflammatory marker 15 for controlled (n = 24), partly con-
trolled (n = 48), and uncontrolled asthma patients (n = 52). Values 
below 20 particles per billion (ppb) were defined as normal.17 One test 
consisted of two FeNO measurements of which the average value 
was taken as the result.
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Patients with a positive skin- prick test and/or specific serum IgE level 
of >0.35 kU/L to HDM or pollen (hazel, ash, alder, birch, common 
timothy, ragweed, mugwort) were defined as sensitized to HDM or, 
respectively, to pollen.
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Patients were separated into a group without ICS and into three 
groups (low, medium, or high dose) with ICS at admission according 
to GINA guidelines. Comparison between admission and discharge 
resulted in six groups: no ICS, ICS lowered 2 or more levels, ICS 
lowered 1 level, ICS level constant, ICS increased 1 level, and ICS in-
creased 2 or more levels. Inhalative long- acting b2- agonists (LABA) 
are administered combined with corticosteroids; therefore, to assess 
the effect of an additional b2- agonist treatment, we split the group, 
in which the ICS level remained constant during the stay, into 4 sub-
groups: no additional LABA at admission and discharge (no LABA), 
LABA added shortly after admission (added LABA), LABA present 
prior to admission and present at discharge (constant LABA). LABA 
were stopped in only one patient within this group (stopped LABA).
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Changes of pulmonary function and airway inflammation were ana-
lyzed by paired t test and Wilcoxon signed- rank test for paired sam-
ples. Differences between groups were analyzed with t tests and 
Mann- Whitney U tests. Stratification and sensitivity analyses were 
performed in order to take into account the following factors: level 
of asthma control, gender, age, sensitization, history of atopic derma-
titis, duration of sojourn, season of the rehabilitation. P - values < .05 
were considered statistically significant. Stata was used for analysis.
|
Informed consent for retrospective data analysis was waived by insti-
tutional and governmental ethics boards.
|
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Among the 344 asthmatic patients, 17.7% were defined as con-
trolled, 45.1% as partly controlled, and 37.2% as uncontrolled 
(Table 1). About 60% of the patients had a history of atopic der-
matitis. Sensitization to HDM was observed in 75.6%, to pollen in 
78.8% of the patients.
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airway inflammation at admission
Pulmonary function parameters at admission were significantly below 
their predicted values on average. Pathologic FeNO (>20 ppb) was 
observed in 97 of 124 (78.2%) patients. Impaired pulmonary function 
and increased FeNO were even present in patients with the allegedly 
best condition—controlled asthma. Mean FEV1 at admission ranged 
from 89.4% [95% confidence interval (CI):86.7%- 92.2%] in patients 
with uncontrolled asthma to 96.8% [95% CI: 93.8%- 99.9%] in patients 
with controlled asthma (Figure 1A). Mean MEF25 at admission ranged 
from 75.7% [69.9%- 81.4%] in patients with uncontrolled asthma to 
93.6% [95% CI: 86.0%- 101.3%] in patients with controlled asthma 
(Figure 1B). Mean MEF75 at admission ranged from 76.5% [95% CI: 
77.0%- 84.5%] in patients with uncontrolled asthma to 93.1% [95% CI: 
88.2%- 98.1%] in patients with controlled asthma (Figure 1C). Median 
FeNO at admission ranged from 27.6 ppb in patients with controlled 
asthma to 49.9 ppb in patients with uncontrolled asthma (Figure 1D).
|
at discharge
Forced expiratory volume in 1 second and MEF75 improved in all pa-
tients. The increase in MEF25 was statistically significant for uncon-
trolled, but not for controlled or partly controlled subjects. Controlled 
individuals showed FEV1 and MEF75 values close to the 100% pre-
dicted benchmark at discharge. The improvement of all three outcome 
parameters was more distinct in the uncontrolled group, absolute 
difference of FEV1: 7.7%, P < .001, MEF75:12.7%, P < .001, and 
MEF25:9.9%, P < .001 (Figure 1A- C).
|
Airway inflammation significantly reduced in all three asthma control 
groups. Reduced FeNO was observed in 114 of 124 patients. From 97 
patients admitted with pathologic FeNO, 68 showed normalized val-
ues (<20 ppb) at discharge. Median FeNO reduced by almost 12 ppb, 
P < .001 for the controlled, by almost 27 ppb, P < .001 for the partly 
controlled and by almost 36 ppb, P < .001 for the uncontrolled group 
(Figure 1D).
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To evaluate a possible effect of the reduced allergen exposure 
due to the moderate altitude, first we stratified the patients in two 
groups, with HDM- sensitization and without HDM- sensitization. 
Uncontrolled and HDM- sensitized patients started rehabilitation with 
slightly less favorable pulmonary conditions (Figure 2). Their pulmo-
nary improvements did not differ from those of non- HDM- sensitized 
patients and ranged at the same margin. A similar pattern was ob-
served regarding airway inflammation. FeNO was reduced in patients 
P < .001) as well as in non- HDM- 
P < .028). While non- HDM- sensitized 
patients started with slightly higher FeNO, the improvement between 
these groups did not differ significantly. Similarly, improvements were 
observed for uncontrolled and pollen- sensitized patients staying in 
autumn/winter and for those staying in the spring/summer. However, 
the difference of improvement between these two groups was not 
significant (data not shown).
Characteristics of the study population
1 75, 
25, n = 344 (%)
Female 134 (39.0) 51 (41.1)
Age (y)
4- 6 78 (22.7)
7- 10 93 (28.5)
11- 15 118 (34.3)
16- 19 50 (14.5)
Level of asthma control
Controlled 61 (17.7) 24 (19.4)
Partly controlled 155 (45.1) 48 (38.7)
Uncontrolled 128 (37.2) 52 (41.9)
Sensitized to
HDM 260 (75.6) 104 (83.9)
Pollen 271 (78.8) 109 (87.9)
Atopic dermatitis 200 (58.1) 71 (57.1)
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rehabilitation effect
Stratified analyses among patients with atopic dermatitis and among 
those without the disease showed that both groups benefited 
significantly from the sojourn. The difference was slightly bigger 
among patients with atopic dermatitis considering FEV1 (patients with 
atopic dermatitis: +4.7%, P < .001 and patients without atopic der-
matitis: +3.3%, P = .003) and slightly smaller considering FeNO (pa-
P < .001 and patients without 
Pulmonary function and 
airway inflammation at admission and 
discharge—stratified for level of asthma 
control. A, B, C, Pulmonary function 
(n = 344) is reported by mean values. 
Circles show patients with controlled 
asthma (n = 61). P –value = comparison 
between discharge and admission, by t 
test for paired samples. Diamonds show 
patients with partly controlled asthma 
(n = 155). Squares show patients with 
uncontrolled asthma (n = 128). D, Airway 
inflammation (n = 124) is reported by 
median values. P –value = comparison 
between discharge and admission, by 
Wilcoxon signed- rank test. Circles show 
patients with controlled asthma (n = 24). 
Diamonds show patients with partly 
controlled asthma (n = 48). Squares show 
patients with uncontrolled asthma (n = 52)
Pulmonary function and 
airway inflammation at admission and 
discharge of patients with uncontrolled 
asthma—stratified for house dust mite 
sensitization. A, B, C, Pulmonary function 
(n = 128) is reported by mean values. P 
- value = comparison between discharge 
and admission, by t test for paired 
samples. Circles show non- sensitized 
patients (n = 26). Squares show sensitized 
patients (n = 102). D, Airway inflammation 
(n = 52) is reported by median values. P 
- value = comparison between discharge 
and admission, by Wilcoxon signed- rank 
test. Circles show non- sensitized patients 
(n = 6). Squares show sensitized patients 
(n = 46)
                  
P < .001) (Figure 3), even though the dif-
ferences of improvement between patients with and without atopic 
dermatitis were not significant.
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In the group whose inhaled corticosteroid dose was elevated 
by one GINA- ICS level, significant improvements (FEV1:+6.6%, 
P P < .001) were observed (Table 2). 
Upon elevation of two or more GINA- ICS- levels, the lung func-
tion improvements were even higher (FEV1:+7.2%, P = .002/
P = .002). Patients with constant GINA- ICS 
level throughout the sojourn showed also increased FEV1:+4.9%, 
P P < .001. Within this 
group, those whose initial, inhalative ICS treatment was sup-
plemented with LABA (added LABA) showed the highest im-
provement of FEV1: 12.5%, P = .004 and largest reduction in 
P = .021. In another subgroup, where LABA 
were already present at admission and remained at discharge, we 
observed a significant FEV1 elevation of 4%, P = .001 and also 
P < .001. Even 
P < .001, while there was no significant change in FEV1, which 
was already 96.9%pred. at admission. Interestingly, we observed 
P = .020 for those whose dose was 
lowered by one GINA- ICS level. FEV1 in this group was already 
100.6%pred. at admission and did not show a significant im-
provement at discharge.
|
longer than 35 days
Among all groups, our findings showed best results for uncon-
trolled subjects if their stay was longer than 35 days. An increase 
in FEV1:+7.6%, P < .001, MEF25:+7%, P = .003, and MEF75:+12.5%, 
P P < .001 
was observed (Figure 4). This group showed also benefits for sojourns 
between 14 and 35 days, but to a lesser extent.
Moreover, stratification and sensitivity analyses concerning the 
factors gender and age did not show a significant difference of im-
provement in favor for any analyzed group (data not shown).
|
In this study, we showed a significant improvement of pulmonary func-
tion and a reduction in airway inflammation of children and adoles-
cents after an inpatient rehabilitation of at least 14 days. Particularly, 
the pulmonary conditions of uncontrolled asthmatic patients improved 
considerably. Sensitization status to pollen or house dust mites did not 
influence the effect of rehabilitation significantly, nor did a concomi-
tant diagnosis of atopic dermatitis. As also the groups with constant 
ICS and without ICS showed pulmonary improvements, an increase in 
ICS was most likely not the only reason for the positive effect of the 
rehabilitation program. An increase in duration of the stay was espe-
cially beneficial to uncontrolled asthmatics.
Previously, numerous studies have shown multiple benefits 
of sojourns at moderate or high altitude, especially for dust mite 
allergic asthmatics.11,17-20 Allergen reduction was discussed as 
the major contributing factor. A recent cohort study of the Dutch 
Asthma Centre in Davos showed improved pulmonary conditions 
of adult asthmatics irrespective of sensitization status.21 In our 
study, uncontrolled asthmatic children and adolescents with HDM- 
sensitization showed similar FEV1 at admission and discharge com-
pared to the Dutch patients. However, our non- HDM- sensitized 
patients had a greater improvement of FEV1. Also, FeNO of our un-
controlled patients was higher at admission, while the reduction at 
discharge was considerably higher after a much shorter time period. 
Pulmonary function and airway inflammation at admission and discharge of patients with asthma—stratified for atopic dermatitis. 
A, Pulmonary function (n = 343) is reported by mean values. P - value = comparison between discharge and admission, by t test for paired 
samples. Diamonds show patients with atopic dermatitis (n = 200). Squares show patients without atopic dermatitis (n = 143). B, Airway 
inflammation (n = 124) is reported by median values. P - value = comparison between discharge and admission, by Wilcoxon signed- rank test. 
Diamonds show patients with atopic dermatitis (n = 71). Squares show patients without atopic dermatitis (n = 53)
                 
Our finding, that non- HDM- sensitized benefit to a similar extent as 
HDM- sensitized, is consistent with finding of the Dutch cohort. As 
pollen- sensitized and non- pollen- sensitized, uncontrolled asthmat-
ics responded within the same range in our study, the reduction in 
exposure to pollen allergens does not fully explain the benefit of 
the stay.
Thus, we further assessed whether the adjustment with asthma 
medication, as it is often inadequate,13,22 was responsible for the ben-
eficial effect. Indeed, our data showed strong effects on lung function 
and airway inflammation for those whose ICS dose was increased. 
However, the striking finding was the reduced airway inflammation 
in patients with no, constant or even decreased ICS. For patients with 
Pulmonary function and airway inflammation at admission and discharge—stratified for change in level of inhalative corticosteroid 
dosage
1
n (344) P n (124) P
Change of GINA ICS level
No ICS 71 96.9 97 .923 22 30.5 20.4 <.001
23 100.6 102.1 .380 8 41.4 17.2 .020
6 109.2 106.7 .770 0 - - - 
ICS level constant 147 92.6 97.5 <.001 52 48.1 15.4 <.001
No LABA 29 95.8 98.4 .450 6 23.1 12.5 .095
Added LABA 17 90.8 103.3 .004 7 63.2 16.4 .021
Constant LABA 100 92.2 96.2 .001 38 49.3 15.9 <.001
Stopped LABA 1 - - - 1 - - - 
ICS + 1 66 88.9 95.5 <.001 31 46.5 15.1 <.001
ICS + 2 31 84.5 91.7 .002 11 51.7 13.2 .002
two GINA levels; ICS level constant, inhalative corticosteroid level not changed; ICS + 1, inhalative corticosteroid elevated by one GINA level; ICS + 2, el-
evated by two GINA levels; No LABA, no additional LABA at admission and discharge; added LABA, LABA added shortly after admission; constant LABA, 
LABA present prior to admission and present at discharge; stopped LABA, LABA were stopped shortly after admission.
Pulmonary function and 
airway inflammation at admission and 
discharge of patients with uncontrolled 
asthma—stratified for duration of the 
sojourn. A, B, C, Pulmonary function 
(n = 128) is reported by mean values. P 
- value = comparison between discharge 
and admission, by t test for paired samples. 
Circles show patients with a stay of 14- 
21 d (n = 30). Diamonds show patients with 
a stay of 22- 35 d (n = 61). Squares show 
patients with a stay of >35 d (n = 37). D, 
Airway inflammation (n = 52) is reported 
by median values. P - value = comparison 
between discharge and admission, by 
Wilcoxon signed- rank test. Circles show 
patients with a stay of 14- 21 d (n = 10). 
Diamonds show patients with a stay of 22- 
35 d (n = 25). Squares show patients with a 
stay of >35 d (n = 17)
                  
constant ICS, lung function also improved significantly, suggesting 
other beneficial factors than the medication adjustment.
Interestingly, there was already a benefit for uncontrolled pa-
tients after a short term stay of 2- 3 weeks, while with prolonged du-
ration of the stay, the benefits accumulated and showed best results 
for this group at 36+ days. This finding underlines the importance 
of time in a given inpatient setting in order for the intervention to 
be successful and provides a reasonable explanation to health in-
surances regarding the minimum length of stay for an uncontrolled 
asthmatic patient.
Our findings suggest that the impact of allergen reduction may 
be overrated, but may still remain a beneficial factor among others 
such as asthma education, corrected inhalation technique, physical 
activity, physiotherapy, and improved adherence leading to optimal 
disease management.15,23-25 In addition, noteworthy are the specific 
climate factors present in moderate altitude, which independently 
have shown positive effects on lung function and airway inflam-
mation and therefore, especially in combination, might also con-
tribute to the observed effect. Among those factors are a low air 
pollution,26 high number of sunshine days, which leads to increased 
vitamin D levels,27 and a reduced gas/air density, which leads to a 
decrease in lung resistances and to an increase in respiratory and 
expiratory flows.28,29
We consider the individualized treatment approach to be a lim-
itation of our study. As due to the personalized rehabilitation sched-
ule and a missing control group, we could not investigate individual 
effects of particular treatment approaches. Moreover, there is no as-
sessment time period after discharge in our patients. A previous study 
assessed long- term effects of inpatient rehabilitation in Germany in 
children with severe forms of asthma.30 Pulmonary function was still 
on a high level in a 12- month follow- up, as well as other outcome pa-
rameters such as school absence, disease management, and quality of 
life improved in the long term.
Thus, further research is needed to evaluate whether the effects 
of rehabilitation programs at moderate altitude can be preserved over 
a longer time period. Also, for a better evaluation of the climate effect, 
a moderate altitude rehabilitation program should be compared to a 
comparable program of a clinic at lower altitude.
In conclusion, we showed that an inpatient rehabilitation program 
at moderate altitude is eligible for improving pulmonary function and 
reducing airway inflammation of children and adolescents, regardless 
their sensitization status to pollen or house dust mites. An inpatient 
rehabilitation program is especially beneficial to patients who are clas-
sified as “uncontrolled” according to the GINA guidelines.
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